LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Cogent Biosciences Inc

Fechado

4.87 2.1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.79

Máximo

4.91

Indicadores-chave

By Trading Economics

Rendimento

-4.1M

-72M

EPS

-0.525

Funcionários

205

EBITDA

-1.2M

-74M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+247.17% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-50M

584M

Abertura anterior

2.77

Fecho anterior

4.87

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de mai. de 2025, 19:39 UTC

Grandes Movimentos do Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 de mai. de 2025, 23:18 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 de mai. de 2025, 22:30 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- Update

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de mai. de 2025, 21:54 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 de mai. de 2025, 21:22 UTC

Conversa de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 de mai. de 2025, 21:17 UTC

Conversa de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 de mai. de 2025, 21:17 UTC

Principais Notícias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 de mai. de 2025, 21:05 UTC

Conversa de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 de mai. de 2025, 20:55 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de mai. de 2025, 20:37 UTC

Principais Notícias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 de mai. de 2025, 20:33 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 de mai. de 2025, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 de mai. de 2025, 20:18 UTC

Principais Notícias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 de mai. de 2025, 20:16 UTC

Principais Notícias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 de mai. de 2025, 20:15 UTC

Ganhos

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 de mai. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: William K. Daniel Joins Board

16 de mai. de 2025, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: Strategic Investment by KKR Completed

16 de mai. de 2025, 20:05 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 19:38 UTC

Conversa de Mercado

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 de mai. de 2025, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 de mai. de 2025, 18:51 UTC

Principais Notícias

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 de mai. de 2025, 18:41 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 18:37 UTC

Conversa de Mercado

Gold Futures End Week on Negative Note -- Market Talk

16 de mai. de 2025, 18:35 UTC

Principais Notícias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 de mai. de 2025, 18:32 UTC

Principais Notícias

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 de mai. de 2025, 18:28 UTC

Conversa de Mercado

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

247.17% parte superior

Previsão para 12 meses

Média 16.56 USD  247.17%

Máximo 24 USD

Mínimo 7 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

7

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.